HONG KONG, Jan. 22, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is excited to announce that the prestigious medical journal Nature Medicine published the results of the company’s independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.